 |
|
 |
|
 |
|
Program |
Partnership |
Call to |
Thursday May 13th |
|
08:30 am |
•
•
• |
ACADEMIC SESSION I Metabolic disorders: global risks, diagnosis and Chair: Brewer Bryan (USA) Aggressive Intervention for Dyslipidemia with the Aim of Controlling Complications in Japanese Diabetic Patients Odawara Masato (Japan) An update of glucose and lipid management in the prevention of stroke Amarenco Pierre (France) Low-dose Aspirin for primary prevention of atherosclerotic events in patients with type II diabetes Ogawa Hisao (Japan) |
10:00 am |
• |
State of the Art Lecture Chair: Fruchart Jean-Charles (France) Metabolic syndrome in the Middle East: a real challenge Al-Rubeaan Khalid (Saudi Arabia) |
10:45 am |
|
Coffee break |
11:15 am |
•
•
•
• |
Symposium sponsored by SOLVAY PHARMACEUTICALS The unfinished business in vascular risk reduction Chair: Fruchart Jean-Charles (France) Defining and addressing the residual vascular risk; the atherogenic dyslipidemia factor Fruchart Jean-Charles (France) How ACCORD will impact the way we treat patients with T2D ? Elam Marshall (USA) FIELD: anything new ? O'Brien Richard (Australia) Fibrates & statins: combination therapy, the way foreward Bersot Thomas (USA) |
12:45 pm |
|
Lunch |
02:00 pm |
•
• |
FONDATION CŒUR ET ARTERES SYMPOSIUM Statins and fibrates in CHD prevention: where are we now ? Chair: Greten Heiner (Germany) First debate: should we give the statins in primary prevention to all people ? Assmann Gerd (Germany) / Packard Chris (UK) Second debate: should we give the fibrates to all diabetic patients ? Zambon Alberto (Italy) / Valensi Paul (France) |
03:30 pm |
|
Coffee Break |
04:00 pm |
•
•
• |
ACADEMIC SESSION II New targets in drug development Chair: Hermans Michel (Belgium) PSCK9: a translationnal research story Krempf Michel (France) Ethnicity and CVD… and what role for the PolyPill in 2010 ? Gupta Sandeep (UK) PPAR α agonist and stroke Duriez Patrick (France) |
